Wellcome Trust funds Kymab mouse platform

Biopharmaceutical company Kymab and the Wellcome Trust’s investment division has announced a £20m Series A equity financing deal, through which Kymab will develop optimised monoclonal antibodies for the treatment of select diseases with high unmet medical need using its proprietary genomically engineered mouse, the Kymouse.

The company will address a broader range of disease targets in partnership with academic organisations and pharmaceutical companies using the Kymouse platform.